Disclosure: This post is written in partnership with Integrated Psychiatry Institute. Level Education Group and its brands CE4Less, AATBS, and CEU Creations may earn a commission if you purchase through the links below.
Mental health professionals enter this field to help people heal. Yet many clinicians quickly encounter a more complex reality in practice. Some clients improve steadily, but others gain insight without meaningful change. Some stabilize for a time, only to relapse. And some do everything “right” yet remain stuck.
This gap between effort and outcome can be difficult to reconcile. It raises deeper questions about what actually drives lasting change, and whether our current models are addressing the full picture of human healing. For thoughtful clinicians, this can be frustrating and painful. Not because they lack skill or care, but because some conditions are complex, entrenched, and resistant to conventional approaches. It’s in this context that psychedelic-assisted therapy is gaining serious attention, offering a fundamentally different approach when conventional methods fall short.
What Is Psychedelic-Assisted Therapy?
Psychedelic-assisted therapy is not simply administering a medicine and hoping healing occurs. It is a structured therapeutic process that unfolds across distinct phases of care, each playing a critical role in the overall outcome.
Depending on legal and clinical settings, this may involve ketamine (currently legal and available in many settings), along with compounds such as psilocybin and MDMA that continue advancing through research and regulatory pathways.
Psychedelic therapy generally includes three phases of treatment:
1. Preparation
Before any medicine session, the therapist helps the client establish safety, readiness, and trust through:
- Clinical screening
- Clarifying treatment goals
- Building therapeutic alliance
- Teaching grounding skills
- Exploring fears and expectations
2. Dosing Session
During the session, the client enters a nonordinary state of consciousness in a carefully supported environment. The therapist’s role is to help maintain safety, presence, and therapeutic containment.
3. Integration
Afterward, the clinician helps the client process insights and translate the experience into meaningful change. This matters because while the medicine may catalyze the experience, therapy often determines whether the experience becomes healing.
Why Clinicians Are Paying Attention
Many clients remain stuck not because they are unmotivated, resistant, or failing therapy. Often, they are dealing with patterns that are difficult to reach through ordinary consciousness alone:
- Trauma stored in the body and nervous system
- Deep shame
- Emotional numbing
- Chronic avoidance
- Rigid beliefs about self or life
- Repetitive depressive thought loops
- Disconnection from meaning, vitality, or hope
These patterns may persist even in clients who are intelligent, self-aware, committed, and highly engaged in treatment. Psychedelic states may temporarily soften these entrenched structures, creating new opportunities for emotional access, insight, and psychological flexibility. For some clinicians, this is the first time they have seen movement in clients who previously plateaued.
Where This Can Matter Most Clinically
Trauma and PTSD
Many trauma survivors can explain their story clearly yet still feel hijacked by triggers, hypervigilance, shutdown, or relational fear. That is because trauma is not only cognitive—it is physiological and relational. When skillfully facilitated, psychedelic-assisted therapy may help clients process trauma through emotional release, somatic awareness, and corrective internal experiences.
Chronic Depression
Some depressed clients have tried years of therapy, medication trials, and insight, yet still feel numb, disconnected, or unable to access hope. Psychedelic therapy may interrupt rigid depressive loops and create openings for reconnection, motivation, and possibility.
Anxiety and Existential Distress
Some clients continue to suffer despite learning coping tools because the roots of their anxiety involve identity, mortality, grief, or existential concerns around meaning and purpose. In these cases, deeper experiential work may create shifts that symptom-management strategies alone cannot reach.
It’s Not Just About the Medicine
One of the biggest misconceptions is that the medicine itself creates the healing. Experienced clinicians know the deeper value often comes from what happens before and after the session.
Without preparation, clients may become overwhelmed. Without integration, profound experiences may fade quickly. With strong therapeutic support, insights can turn into:
- Lasting behavior change
- Improved emotional regulation
- Reduced avoidance
- Healthier relationships
- Greater self-compassion
- Renewed purpose and momentum
That is why therapists remain central to outcomes.
Why Specialized Training Matters
Psychedelic-assisted therapy requires skills beyond conventional talk therapy. Clients in altered states may become highly vulnerable, emotionally open, and psychologically suggestible. Standard interventions that work well in ordinary sessions may be ineffective – or even disruptive – during these states.
Proper training often includes:
- Working with nonordinary states of consciousness
- Trauma-informed care
- Somatic and nervous system awareness
- Ethical boundaries in vulnerable states
- Managing difficult experiences
- Integration frameworks
- Screening and contraindications
- Collaboration with medical providers
This is not simply therapy plus a medicine session. It is a specialized modality requiring clinical maturity, judgment, and training.
Why This Matters Right Now
Many clinicians are already hearing questions like:
- “What do you think about ketamine therapy?”
- “Can psychedelic therapy help trauma?”
- “Should I try psilocybin?”
- “Do you offer integration support?”
- “My other treatments haven’t worked. What else could I try?”
Even clinicians who never facilitate dosing sessions benefit from understanding this modality so they can guide clients ethically, intelligently, and responsibly. This need is only increasing as policy momentum builds. A recent executive action from the White House aimed at accelerating medical treatments for serious mental illness signals growing federal support for faster review pathways in the U.S. Food and Drug Administration. This could shorten timelines for therapies such as MDMA and psilocybin treatment, with potential approvals emerging later this year.
The Bottom Line
Psychedelic-assisted therapy is not a shortcut and not a cure-all. It is an emerging clinical modality with real promise for some of the clients who remain most difficult to help with existing tools alone. For many clinicians, the question is no longer whether to pay attention, but how to understand this modality deeply enough to guide clients safely, ethically, and responsibly.
Keith Kurlander, MA, LPC is co-author of the New York Times bestselling book Psychedelic Therapy, co-founder of the Integrative Psychiatry Institute (IPI), and co-host of the Higher Practice Podcast. At age 19, following a challenging psilocybin experience, Keith faced severe mental health challenges that persisted into adulthood. Drawing from both his personal healing and over 20 years as a psychotherapist and coach, he has dedicated his career to advancing and innovating mental healthcare.
Will Van Derveer, MD is a psychiatrist and co-author of New York Times bestseller, Psychedelic Therapy. He is a leader in the movement to upgrade mental healthcare by addressing root causes of suffering, rather than only medicating symptoms. After staffing several psychedelic therapy clinical trials, Dr. Van Derveer co-founded Integrative Psychiatry Institute (IPI), which has trained 10,000 licensed professionals in integrative psychiatry and psychedelic assisted therapy.